Trust Co. of Vermont Has $202,000 Stock Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Trust Co. of Vermont increased its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 26.8% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 502 shares of the pharmaceutical company’s stock after buying an additional 106 shares during the quarter. Trust Co. of Vermont’s holdings in Vertex Pharmaceuticals were worth $202,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of the company. Benjamin F. Edwards & Company Inc. grew its holdings in shares of Vertex Pharmaceuticals by 18.8% in the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 5,892 shares of the pharmaceutical company’s stock valued at $2,761,000 after acquiring an additional 932 shares in the last quarter. Pacer Advisors Inc. raised its stake in Vertex Pharmaceuticals by 2.9% in the second quarter. Pacer Advisors Inc. now owns 38,326 shares of the pharmaceutical company’s stock valued at $17,964,000 after buying an additional 1,085 shares during the period. Thrivent Financial for Lutherans boosted its position in Vertex Pharmaceuticals by 6.5% during the second quarter. Thrivent Financial for Lutherans now owns 94,794 shares of the pharmaceutical company’s stock worth $44,432,000 after purchasing an additional 5,827 shares during the period. Summit Trail Advisors LLC raised its holdings in Vertex Pharmaceuticals by 14.8% in the 2nd quarter. Summit Trail Advisors LLC now owns 2,881 shares of the pharmaceutical company’s stock valued at $1,350,000 after acquiring an additional 372 shares during the period. Finally, Profund Advisors LLC lifted its position in Vertex Pharmaceuticals by 12.1% during the second quarter. Profund Advisors LLC now owns 29,546 shares of the pharmaceutical company’s stock worth $13,849,000 after acquiring an additional 3,194 shares during the last quarter. Institutional investors own 90.96% of the company’s stock.

Vertex Pharmaceuticals Stock Performance

Shares of VRTX opened at $422.00 on Monday. The firm has a market capitalization of $108.68 billion, a P/E ratio of -212.06, a P/E/G ratio of 2.11 and a beta of 0.40. Vertex Pharmaceuticals Incorporated has a 52 week low of $377.85 and a 52 week high of $519.88. The stock has a 50 day moving average price of $440.94 and a two-hundred day moving average price of $466.09. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.20 and a current ratio of 2.47.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its earnings results on Monday, November 4th. The pharmaceutical company reported $4.38 EPS for the quarter, beating the consensus estimate of $3.61 by $0.77. Vertex Pharmaceuticals had a negative net margin of 4.52% and a negative return on equity of 1.91%. The company had revenue of $2.77 billion during the quarter, compared to the consensus estimate of $2.69 billion. During the same quarter in the prior year, the company posted $3.67 earnings per share. The firm’s revenue for the quarter was up 11.6% on a year-over-year basis. Equities analysts forecast that Vertex Pharmaceuticals Incorporated will post -1.9 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several analysts have weighed in on the stock. Royal Bank of Canada lifted their price objective on shares of Vertex Pharmaceuticals from $437.00 to $451.00 and gave the stock a “sector perform” rating in a research note on Tuesday, November 5th. Needham & Company LLC reissued a “hold” rating on shares of Vertex Pharmaceuticals in a research note on Friday, December 20th. Stifel Nicolaus boosted their target price on shares of Vertex Pharmaceuticals from $490.00 to $494.00 and gave the stock a “hold” rating in a research note on Monday, December 16th. Oppenheimer cut Vertex Pharmaceuticals from an “outperform” rating to a “market perform” rating in a report on Thursday, December 19th. Finally, William Blair reiterated an “outperform” rating on shares of Vertex Pharmaceuticals in a report on Monday, January 13th. Three research analysts have rated the stock with a sell rating, ten have given a hold rating, eighteen have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $490.38.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.